The only peptide with a direct, central-acting mechanism for increasing sexual desire in both men and women — FDA-approved as Vyleesi for women, widely prescribed off-label for men.
| Provider | Type | Price | Review | Link |
|---|---|---|---|---|
| Marek Health | Telehealth | $166/mo | Read review | Get Started → |
| Limitless Alt Med | Telehealth | $115–$275/mo | Read review | Get Started → |
| Defy Medical | Telehealth | ~$200/mo | Read review | Get Started → |
| NextGenPeps | Research | $41 / 10mg | — | Visit Site → |
| Alpha Peptides | Research | $26.90 / 10mg | — | Visit Site → |
Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →
PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone (α-MSH). It was originally developed as a potential sunless tanning agent from Melanotan II, but researchers discovered a pronounced sexual arousal effect during early trials. It was subsequently developed by Palatin Technologies and received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Unlike PDE5 inhibitors (Viagra, Cialis) which work peripherally by increasing blood flow, PT-141 activates melanocortin receptors MC3R and MC4R in the central nervous system — specifically in the hypothalamus. This produces a genuine increase in sexual motivation and desire rather than simply a mechanical vascular response. This central mechanism makes it effective for both men and women and for cases where psychological factors drive low libido.
Onset is typically 45–60 minutes after subcutaneous injection, with effects lasting 6–12 hours. Most users report noticeably increased sexual desire and arousal. Common side effects include transient nausea (particularly at higher doses), flushing, and mild headache — usually subsiding within 1–2 hours. These can be minimized by starting at 0.5–1mg and timing the dose with food.
Use code 3LUIZH10 at NextGenPeps for a discount on PT-141.